39 results about "Vancomycin-Resistant Enterococci" patented technology

The present invention relates to characterizing changes in mammalian bacterial gastrointestinal, cutaneous and nasal microbiota associated with antibiotic treatment and various disease conditions (such as asthma, allergy, obesity, metabolic syndrome, gastrointestinal reflux disease (GERD), eosinophilic esophagitis, gastro-esophageal junction adenocarcinomas (GEJAC), infections due to bacteria that are resistant to antibiotics, including Methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile, vancomycin-resistant enterococci, etc.) and related diagnostic and therapeutic methods. Therapeutic methods of the invention involve the use of live bacterial inoculants that are capable of restoring healthy mammalian bacterial gastrointestinal, skin, and nasal microbiota.

The invention belongs to the field of novel medicines and compounds, and discloses a thiazole orange styrene derivative, a method for preparing the same and application of the thiazole orange styrene derivative to preparing medicines capable of resisting medicine-resistant bacteria. The thiazole orange styrene derivative is of a structure shown as a formula (I). An R in the formula is defined as an instruction book. The method includes carrying out condensation reaction on thiazole orange analogues and different types of aromatic aldehyde to obtain the thiazole orange styrene derivative. The thiazole orange styrene derivative, the method and the application have the advantages that the method is simple, and raw materials for the thiazole orange styrene derivative are easily available; excellent interaction between the thiazole orange styrene derivative and bacterium division proteins FtsZ can be realized, and accordingly reproduction of diversified medicine-resistant bacteria such as vancomycin-resistant enterococci and methicillin-resistant staphylococcus aureus can be inhibited; the thiazole orange styrene derivative is little in toxic and side effect and has a prospect of being developed to obtain novel antibiotic medicines.

The present invention relates to methods for detecting the presence or absence of vancomycin resistant enterococci (VRE) in a sample using a multiplex polymerase chain reaction (mtx-PCR) assay. Furthermore, the present invention relates to oligonucleotide primers and kits for the detection of VRE.

The invention belongs to the technical field of antibacterial drugs and relates to 4-hydroxy-2-quinolone-nitrogen-(4-quinazolinone)-3-formamide derivatives as well as a preparation method and an application thereof as an antibacterial drug. The compounds are shown in a formula (I), wherein R1 is selected from hydrogen, trifluoromethyl, C1-C8 alkyl, C1-C8 alkoxy and halogen; R2 is selected from hydrogen, nitryl, C1-C8 alkyl, C1-C8 alkoxy and halogen; R3 is selected from C1-C8 alkyl and aryl methyl; R4 is selected from C1-C8 alkyl. The 4-hydroxy-2-quinolone-nitrogen-(4-quinazolinone)-3-formamidederivatives are first discovered antibacterial compounds of novel structures, the compounds have higher inhibition functions on gram-positive bacteria including staphylococcus aureus, staphylococcusepidermidis, enterococcus and the like, particularly, drug-resistant gram-positive bacteria (MRSA (methicillin-resistant staphylococcus aureus), MRSE (methicillin-resistant staphylococcus epidermidis)and VRE (vancomycin-resistant enterococci)) and can be used for following further modification and development.

The invention discloses an antimicrobial peptide, which has the sequence as follow: Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-X1-X2-Arg-Arg-Leu-Trp-Gly-Ala, wherein the X1 is selected from Lys, Arg, Trp, Leu, Phe and Tyr; and the X2 is selected from Trp, Arg, Lys, Phe, Ser and His. The antimicrobial peptide has an obvious inhibiting effect on methicillin-resistant s. aureus, vancomycin-resistant enterococci, carbapenem-resistant pseudomonas aeruginosa and carbapenem-resistant klebsiella pneumoniae, and has lower hemolytic activity, good stability, high antimicrobial activity, and an efficient broad-spectrum bacteriostatic action.

The present invention relates to a new use of a fermented soy extracts in preventing VRE infections.

A presence/absence test for Staphylococcus aureus (S. aureus) involves placing a first generation test sample in a solution that will clot in the presence of S. aureus. The solution contains components that will selectively grow S. aureus and also contains clotting factors that will react with S. aureus, if S. aureus is present in the sample, to clot the solution. Examples of specimen samples that can be tested include nasal swabs and lesion swabs, among others. The test can also be modified to detect the presence or absence of methicillin resistant S. Aureus (MRSA). The addition of micro particles having a size in the range of about 0.1 micron to about 1.0 mm provides localities where the bacteria agglomerate, thereby significantly decreasing the clotting time, and providing a significantly stronger clot. The micro particles can be used in other bacteria tests to accelerate the production of an end result. Such other tests can include a vancomycin-resistant enterococcus test; a Group B Streptococcus test; a test for hemolytic E. coli; and a test for Listeria monocytogenes, to name a few. These tests are all performed in a liquid broth-type reagent mixture and do not necessarily involve clotting of the broth.

The invention provides a 4-hydroxybenzoylacrylic acid derivative. The 4-hydroxybenzoylacrylic acid derivative is a compound which is represented as formula I, wherein R1 is C1-C8 alkyl, C1-C8 alkyl which is substituted by halogen or hydroxyl, C6-C8 aryl, C1-C9 alkanoyl or C6-C9 aroyl; and R2 is C1-C8 alkyl, C6-C8 aryl, C1-C8 alkylamino or C6-C8 arylamino. The 4-hydroxybenzoylacrylic acid derivative has inhibitory activity for mycobacterium tuberculosis protein kinase PknB can inhibit mycobacterium tuberculosis, multidrug resistant mycobacterium tuberculosis and several drug resistant Gram-positive bacterium such as methicillin-resistant staphylococcus aureus, methicillin-resistant staphylococcus epidermidis and vancomycin-resistant enterococci, no cross resistance exists in the 4-hydroxybenzoylacrylic acid derivative and existing antibiotics and the 4-hydroxybenzoylacrylic acid derivative has good antibacterial effect.

The present invention relates to methods and compositions for reducing the risk and severity of vancomycin-resistant Enterococci infection or colonization. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacteria Clostridium scindens and/or the bacteria Blautia producta contribute substantially to resistance against vancomycin-resistant Enterococci infection or colonization. Without being bound by any particular theory, it is believed that this is achieved through the biosynthesis of secondary bile acids in the case of Clostridium scindens.

The invention relates to an indole full dione thiosemicarbazone type compound and a use thereof in preparation of anti-medicament-resistant bacteria medicaments. The indole full dione thiosemicarbazone type compound provided by the invention has a very strong effect on inhibiting methicillin-resistant Staphylococcus aurei (MRSA) and vancomycin-resistant enterococci (VRE) and can be used for preparing the novel and effective anti-medicament-resistant bacteria medicaments. The medicaments can be prepared into injections, tablets, pills, capsules, suspensions or emulsions for use. A medicament delivery way can adopt oral medication and transdermal, intravenous or intramuscular injection. The chemical structural formula of the indole full dione derivative provided by the invention is as shown in formula (I), and in the formula, R1 is o-CH3, o-OCH3, o-F, m-CH3, m-OCH3, m-F, m-Cl, p-CH3, p-OCH3, p-F, p-Cl, p-Br or H; and R2 is CH3, F, Cl, Br, I or H.

An Apparatus that generates onsite three antimicrobial solutions by electrolyzing a dilute brine solution. At least one of the generated solutions can be used to dissolve protein, emulsify oils and fats making it an effective general purpose cleaner. A second solution can be used as a non-corrosive, fast active general purpose sanitizer and a third solution can be used as a high level disinfectant, capable of killing all microorganism, including MRSA (methicillin resistant staphylococcus aureaus), C. diff (clostridium difficle), VRE (vancomycin resistant enterococci) and acinetobactor baumannii. The onsite generated antimicrobial solutions reduce the occurrence of infectious diseases in hospitals, other human or animal health care settings, cruise-ships, hotels and other facilities whereas there is a higher risk of spreading infectious diseases.

The invention belongs to the technical field of antibacterial medicines, and relates to a 1-substituted benzoyl-4-fatty acylsemicarbazide derivative, a preparation method thereof, and a use thereof as an antibacterial medicine. The compound is represented by formula (I); and in the formula (I), R1 is selected from hydrogen, a hydroxyl group, a C1-C8 alkyl group, a C1-C8 alkoxy group, an arylmethoxy group and a halogenated arylmethoxy group, R2 is selected from hydrogen, a C1-C8 alkyl group and a halogenated C1-C8 alkyl group, and X is selected from sulfur and oxygen. The 1-substituted benzoyl-4-fatty acylsemicarbazide derivative of the present invention has a strong inhibition effect on Gram-positive bacteria, especially methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant Staphylococcus epidermidis (MRSE) and vancomycin-resistant enterococci (VRE), and can be used for preparing novel drug-resistant bacteria medicines.

The present invention relates to uses of Macrolactin A produced by Bacillus polyfermenticus KJS-2 (KCCM 10769P), which is a new bacillus strain, as an antibiotic. Macrolactin A of the present invention, which is produced by Bacillus polyfermenticus KJS-2, shows a broad spectrum of antibiotic activity against a variety of microorganisms and fungi, and is proved to be very efficient for the inhibition of particularly vancomycin-resistant enterococci (VRE) and methicillin-resistant Staphylococcus Aureus (MRSA) that are multidrug-resistant bacteria. The antibiotic Macrolactin A produced by Bacillus polyfermenticus KJS-2, can be used as an excellent antibiotic against vancomycin-resistant enterococci (VRE) and methicillin-resistant Staphylococcus Aureus (MRSA), and thus the present invention is a very useful invention for medical industry.

Novel oxazolidinone derivatives with a difluorophenyl moiety, represented by Chemical Formula 1, pharmaceutically acceptable salts thereof, a preparation method thereof, and a pharmaceutical composition containing the same as an active ingredient are provided. Exhibiting potent inhibitory activity against Gram-positive bacteria including Haemophilus influenza and Coagulase negative staphylococci and resistant bacteria including vancomycin-resistant enterococci (VRE), the pharmaceutical composition is useful as an antibiotic.

The invention belongs to the field of medicinal chemistry, and discloses antibacterially active linezolid alkali cation amphiphilic compounds and a synthesis method thereof. Three target products are obtained simply and quickly through a two-step or three-step reaction. The main structure is as follows: in-vitro antibacterial activity experiments show that the series of compounds show good antibacterial effects on sensitive strains such as staphylococcus aureus, Enterococcus faecalis, Escherichia coli and Salmonella enteric, and some of the compounds show excellent antibacterial effects on super bacteria including methicillin-resistant staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE) and carbapenemases-producing Enterobacteriaceae (CRE). In-vitro erythrocytotoxicity experiments show that the series of compounds have less erythrocytotoxicity, and the series of compounds are expected to be used as new antibacterial drug candidates.

The present invention provides microbe disinfectants, providing: Drug-resistant microbe disinfectants comprising a chlorous acid aqueous solution for inactivating microbes selected from methicillin-resistant Staphylococcus aureus, multidrug-resistant Pseudomonas aeruginosa, and vancomycin-resistant Enterococcus; and microbe disinfectants, which are made with acidity when applied to gram-negative microbes and with alkalinity when applied to gram-positive microbes. The microbes comprise at least one species of microbes selected from the group consisting of E. coli, Staphylococcus aureus, microbes of genus Bacillus, microbes of genus Paenibacillus, Pseudomonas aeruginosa, Enterococcus, Salmonella enterica, and periodontal disease microbes. The present invention is usable as a microbe disinfectant that is safe to human body and easy to handle as a microbe disinfectant for pretreatment in food processing and produces chlorous acid that generates little chlorine dioxide. The microbe disinfectant comprising a chlorous acid aqueous solution of the present invention can be utilized as a sterilizing agent, food additive, antiseptic, quasi-drug, medicine, etc.

The invention discloses a pharmaceutical composition and application thereof. The pharmaceutical composition is a compound shown as a chemical formula (I) or pharmaceutically acceptable salts and pharmaceutically acceptable carriers thereof: (the formula is shown in the description). The compound can be used for preparing an antibacterial drug, in particular preparing a medicine for preventing or treating vancomycin-resistant bacteria infectious diseases. Experimental data show that the compound is combined with glycopeptide antibacterial drugs, so that the growth of vancomycin-resistant enterococci can be effectively inhibited.